9-28 | Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB.
9-19 | Ahead of the global tuberculosis High-Level Meeting at the United Nations, MSF calls on Johnson & Johnson not to enforce any secondary patents for bedaquiline in any country with a high burden of TB.We also call on Cepheid to drop the price of the GeneXpert TB test from US$10 to US$5 in order to save lives.
8-10 | In July 2023, Médecins Sans Frontières (MSF) closed the chapter on one of its longest standing projects in Malawi, launched some 25 years ago in response to the HIV/AIDS epidemic.
10-7 | Almost one million people are currently displaced in northern Mozambique after fleeing their homes in search of safety, due to the conflict that started in Cabo Delgado province in October 2017. Many people have been displaced multiple times, needing to abandon their few possessions, means of survival, loved ones and communities during each displacement. Living through such a prolonged conflict, with little to no prospect of a stable future, comes with profound mental health consequences.
5-17 | Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB-PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World Health Organization (WHO) have announced it will update global guidance on treatment. Following the results of MSF’s trial the WHO are now recommending programmatic use of the 6- month BPaLM regimen – comprising bedaquiline, pretomanid, linezolid (600 mg) and moxifloxacin in MDR-TB patients in pla